• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用 TCGA 队列验证和扩展 Lund 膀胱癌分类法并进行描述。

A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort.

机构信息

Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.

Division of Urological Research, Department of Translational Medicine, Lund University, Skåne University Hospital, Malmö, Sweden.

出版信息

Sci Rep. 2018 Feb 27;8(1):3737. doi: 10.1038/s41598-018-22126-x.

DOI:10.1038/s41598-018-22126-x
PMID:29487377
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5829240/
Abstract

Global gene expression analysis has been a major tool for urothelial carcinoma subtype discovery. This approach has revealed extensive complexity both in intrinsic features of the tumor cells and in the microenvironment. However, global gene expression cannot distinguish between gene expression signals originating from the tumor cells proper and from normal cells in the biopsy. Here, we use a large cohort of advanced urothelial carcinomas for which both gene expression data and extensive immunohistochemistry are available to create a supervised mRNA expression centroid classifier. This classifier identifies the major Lund taxonomy tumor cell phenotypes as defined by IHC. We apply this classifier to the independent TCGA dataset and show excellent associations between identified subtypes and genomic features. We validate a progressed version of Urothelial-like A (UroA-Prog) that shows FGFR3 mutations and CDKN2A deletions, and we show that the variant Urothelial-like C is almost devoid of FGFR3 mutations. We show that Genomically Unstable tumors are very distinct from Urothelial-like tumors at the genomic level, and that tumors classified as Basal/SCC-like all complied with the established definition for Basal/SCC-like tumors. We identify the Mesenchymal-like and Small-cell/Neuroendocrine-like subtypes, and demonstrate that patients with UroB and Sc/NE-like tumors show the worst overall survival.

摘要

全球基因表达分析一直是发现尿路上皮癌亚型的主要工具。这种方法不仅揭示了肿瘤细胞内在特征的复杂性,还揭示了肿瘤微环境的复杂性。然而,全局基因表达并不能区分源自肿瘤细胞本身的基因表达信号和活检中正常细胞的基因表达信号。在这里,我们使用了大量的高级尿路上皮癌病例,这些病例既有基因表达数据,又有广泛的免疫组织化学数据,我们可以用这些数据来创建一个受监督的 mRNA 表达质心分类器。这个分类器可以识别出由 IHC 定义的 Lund 分类法肿瘤细胞表型的主要亚型。我们将这个分类器应用于独立的 TCGA 数据集,并显示出识别出的亚型与基因组特征之间的良好关联。我们验证了经过改进的尿路上皮样 A(UroA-Prog)亚型,该亚型显示 FGFR3 突变和 CDKN2A 缺失,并且我们发现变体尿路上皮样 C 几乎没有 FGFR3 突变。我们表明,基因组不稳定的肿瘤在基因组水平上与尿路上皮样肿瘤非常不同,并且被归类为基底/鳞癌样的肿瘤都符合基底/鳞癌样肿瘤的既定定义。我们鉴定了间充质样和小细胞/神经内分泌样亚型,并证明 UroB 和 Sc/NE 样肿瘤患者的总体生存率最差。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c3/5829240/6112e8f589ee/41598_2018_22126_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c3/5829240/a6609240a6b7/41598_2018_22126_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c3/5829240/bb88b2643ae3/41598_2018_22126_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c3/5829240/83a60bcf15a1/41598_2018_22126_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c3/5829240/576368a57ad6/41598_2018_22126_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c3/5829240/88f7b56f074f/41598_2018_22126_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c3/5829240/9d19a0ba505e/41598_2018_22126_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c3/5829240/6112e8f589ee/41598_2018_22126_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c3/5829240/a6609240a6b7/41598_2018_22126_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c3/5829240/bb88b2643ae3/41598_2018_22126_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c3/5829240/83a60bcf15a1/41598_2018_22126_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c3/5829240/576368a57ad6/41598_2018_22126_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c3/5829240/88f7b56f074f/41598_2018_22126_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c3/5829240/9d19a0ba505e/41598_2018_22126_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c3/5829240/6112e8f589ee/41598_2018_22126_Fig7_HTML.jpg

相似文献

1
A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort.使用 TCGA 队列验证和扩展 Lund 膀胱癌分类法并进行描述。
Sci Rep. 2018 Feb 27;8(1):3737. doi: 10.1038/s41598-018-22126-x.
2
The Lund Molecular Taxonomy Applied to Non-Muscle-Invasive Urothelial Carcinoma.Lund 分子分类法在非肌肉浸润性尿路上皮癌中的应用。
J Mol Diagn. 2022 Sep;24(9):992-1008. doi: 10.1016/j.jmoldx.2022.05.006. Epub 2022 Jul 16.
3
Molecular subtype classification of urothelial carcinoma in Lynch syndrome.林奇综合征中尿路上皮癌的分子亚型分类。
Mol Oncol. 2018 Aug;12(8):1286-1295. doi: 10.1002/1878-0261.12325. Epub 2018 Jun 19.
4
Toward a molecular pathologic classification of urothelial carcinoma.朝着膀胱癌的分子病理分类发展。
Am J Pathol. 2013 Sep;183(3):681-91. doi: 10.1016/j.ajpath.2013.05.013. Epub 2013 Jul 1.
5
Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.尿路上皮膀胱癌的分子亚型:来自 2411 例肿瘤的荟萃分析队列研究结果。
Eur Urol. 2019 Mar;75(3):423-432. doi: 10.1016/j.eururo.2018.08.027. Epub 2018 Sep 10.
6
Molecular pathology of the luminal class of urothelial tumors.尿路上皮肿瘤 luminal 型的分子病理学。
J Pathol. 2019 Nov;249(3):308-318. doi: 10.1002/path.5318. Epub 2019 Aug 27.
7
HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts.人表皮生长因子受体2(HER2)和表皮生长因子受体(EGFR)在尿路上皮癌中的扩增和表达发生在不同的生物学和分子背景下。
Oncotarget. 2017 Jul 25;8(30):48905-48914. doi: 10.18632/oncotarget.16554.
8
Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.靶向 DNA 和 RNA 测序联合分析尿路上皮癌和鳞状细胞膀胱癌揭示了不同的基因组和转录组事件以及独特的治疗意义。
Eur Urol. 2018 Dec;74(6):741-753. doi: 10.1016/j.eururo.2018.06.047. Epub 2018 Jul 20.
9
Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification.尿路上皮癌的分子分类:整体mRNA分类与肿瘤细胞表型分类
J Pathol. 2017 May;242(1):113-125. doi: 10.1002/path.4886. Epub 2017 Mar 28.
10
Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems.尿路上皮癌的分子亚型由特定的基因调控系统所定义。
BMC Med Genomics. 2015 May 26;8:25. doi: 10.1186/s12920-015-0101-5.

引用本文的文献

1
Molecular Characteristics, Heterogeneity, Plasticity, and Cell of Origin of Neuroendocrine Bladder Cancer.神经内分泌膀胱癌的分子特征、异质性、可塑性及起源细胞
Cancer Heterog Plast. 2025;2(1). doi: 10.47248/chp2502010005. Epub 2025 Mar 6.
2
HER2 and urothelial carcinoma: current understanding and future directions.人表皮生长因子受体2(HER2)与尿路上皮癌:当前认识与未来方向
Nat Rev Urol. 2025 Aug 15. doi: 10.1038/s41585-025-01075-x.
3
Deciphering riddles in molecular subtyping of bladder cancer.解读膀胱癌分子亚型中的谜题。

本文引用的文献

1
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.肌层浸润性膀胱癌分子亚型对新辅助化疗后反应和生存预测的影响。
Eur Urol. 2017 Oct;72(4):544-554. doi: 10.1016/j.eururo.2017.03.030. Epub 2017 Apr 5.
2
HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts.人表皮生长因子受体2(HER2)和表皮生长因子受体(EGFR)在尿路上皮癌中的扩增和表达发生在不同的生物学和分子背景下。
Oncotarget. 2017 Jul 25;8(30):48905-48914. doi: 10.18632/oncotarget.16554.
3
Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.
Asian J Urol. 2025 Apr;12(2):217-231. doi: 10.1016/j.ajur.2024.09.006. Epub 2024 Dec 5.
4
PTEN loss drives p53 LOH and immune evasion in a novel urothelial organoid model harboring p53 missense mutations.在一个携带p53错义突变的新型尿路上皮类器官模型中,PTEN缺失导致p53杂合性缺失和免疫逃逸。
Oncogene. 2025 May;44(19):1336-1349. doi: 10.1038/s41388-025-03311-5. Epub 2025 Feb 22.
5
Molecular classification using Lund University algorithm and clinical correlations in muscle-invasive bladder cancer: Insights from a retrospective study.使用隆德大学算法进行分子分类及肌肉浸润性膀胱癌的临床相关性:一项回顾性研究的见解
Bladder (San Franc). 2024 Nov 27;11(4):e21200019. doi: 10.14440/bladder.2024.0031. eCollection 2024.
6
The combination treatment of RC48 and STAT3 inhibitor acts as a promising therapeutic strategy for basal bladder cancer.RC48与STAT3抑制剂的联合治疗是一种有前景的基底膀胱癌治疗策略。
Front Immunol. 2025 Jan 7;15:1432586. doi: 10.3389/fimmu.2024.1432586. eCollection 2024.
7
Molecular profiling of bladder cancer xenografts defines relevant molecular subtypes and provides a resource for biomarker discovery.膀胱癌异种移植瘤的分子谱分析确定了相关分子亚型,并为生物标志物发现提供了资源。
Transl Oncol. 2025 Feb;52:102269. doi: 10.1016/j.tranon.2024.102269. Epub 2025 Jan 13.
8
Comprehensive genomic characterization of early-stage bladder cancer.早期膀胱癌的综合基因组特征分析
Nat Genet. 2025 Jan;57(1):115-125. doi: 10.1038/s41588-024-02030-z. Epub 2025 Jan 3.
9
Proteomic analysis of non-muscle invasive and muscle invasive bladder cancer highlights distinct subgroups with metabolic, matrisomal, and immune hallmarks and emphasizes importance of the stromal compartment.非肌肉浸润性和肌肉浸润性膀胱癌的蛋白质组学分析突出了具有代谢、基质和免疫特征的不同亚组,并强调了基质区室的重要性。
J Pathol. 2025 Jan;265(1):41-56. doi: 10.1002/path.6367. Epub 2024 Nov 25.
10
Molecular Subtypes Are Associated With Clinical Benefit in Cisplatin-Treated Metastatic Urothelial Cancer Patients.分子亚型与顺铂治疗的转移性尿路上皮癌患者的临床获益相关。
JCO Precis Oncol. 2024 Oct;8:e2400209. doi: 10.1200/PO.24.00209. Epub 2024 Oct 2.
膀胱癌分子亚型的遗传改变:癌症基因组图谱数据集的说明。
Eur Urol. 2017 Sep;72(3):354-365. doi: 10.1016/j.eururo.2017.03.010. Epub 2017 Mar 30.
4
Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy.肌层浸润性膀胱癌中 Her2 改变:靶向治疗的蛋白表达以外的患者选择。
Sci Rep. 2017 Feb 16;7:42713. doi: 10.1038/srep42713.
5
Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification.尿路上皮癌的分子分类:整体mRNA分类与肿瘤细胞表型分类
J Pathol. 2017 May;242(1):113-125. doi: 10.1002/path.4886. Epub 2017 Mar 28.
6
The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.溴结构域抑制剂OTX015(MK-8628)在三阴性乳腺癌模型中作为单一药物以及与依维莫司联合使用时均具有抗肿瘤活性。
Oncotarget. 2017 Jan 31;8(5):7598-7613. doi: 10.18632/oncotarget.13814.
7
OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.OTX015(MK-8628)是一种新型的溴结构域和超末端结构域(BET)抑制剂,在携带不同致癌突变的非小细胞肺癌和小细胞肺癌模型中显示出抗肿瘤活性。
Oncotarget. 2016 Dec 20;7(51):84675-84687. doi: 10.18632/oncotarget.13181.
8
Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression.利用基因表达估算组织浸润性免疫细胞和基质细胞群体的总体丰度。
Genome Biol. 2016 Oct 20;17(1):218. doi: 10.1186/s13059-016-1070-5.
9
Claudin-low bladder tumors are immune infiltrated and actively immune suppressed.Claudin-low 膀胱癌肿瘤具有免疫浸润性,并受到积极的免疫抑制。
JCI Insight. 2016 Mar 17;1(3):e85902. doi: 10.1172/jci.insight.85902.
10
Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.膀胱癌管腔和基底亚型的荟萃分析及用于临床的特征性免疫组织化学标志物的鉴定。
EBioMedicine. 2016 Oct;12:105-117. doi: 10.1016/j.ebiom.2016.08.036. Epub 2016 Aug 25.